Blood Cancer Talks
This podcast focuses exclusively on the management of blood cancers and hematology. The twice-monthly episodes are hosted by Rajshekhar Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD.
Advertisement
Raajit Rampal, MD, PhD, and the "Blood Cancer Talks" hosts discuss the diagnosis and management of essential thrombocythemia.
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
KarMMa-3 trial evaluated ide-cel in MM, while the CARTITUDE-4 trial evaluated cilta-cel in MM.
Dr. Tefferi discussed choosing the right mentors, balancing the clinical and the research, and becoming a "master physician."
Dr. Dispenzieri, of the Mayo Clinic, joins the "Blood Cancer Talks" hosts to discuss how to treat and manage AL amyloidosis.
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Advertisement
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Shernan Holtan, MD, and the hosts discuss recent data on graft versus host disease prophylaxis.
Dr. Derman and the hosts discuss myeloma abstracts from ASH 2023, including the PERSEUS trial and the KarMMa-3 trial.
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Alexander Perl, MD, joins the hosts to discuss the management of newly diagnosed and relapsed FLT3-positive AML.
The episode also discusses Dr. Raza's book, "The First Cell," which recounts stories of her patients with terminal cancer.
Kate Cwynarski, MBBS, PhD, of the University of College London, discusses the management of CNS lymphomas.
This episode of "Blood Cancer Talks" discusses the biology and management of multiple myeloma and the role of venetoclax.
The episode also highlights the S1211 study, which is the first randomized controlled trial with high-risk enrichment in MM.
Dr. Horwitz and the hosts focus on the three most common types of PTCL and the latest research.
Uma Borate, MBBS, joins the hosts to discuss CCUS and the latest data.
Dr. Brodsky and the hosts discuss treatment options for PNH and key recent research on the subject.
Dr. Bartlett and the hosts explore the history of first-line treatments for patients with Hodgkin lymphoma.
Dr. Jain discusses how he addresses the acute toxicities that can arise after CAR T-cell therapy.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.